Phaseline

Companies › ParVation Therapeutics

ParVation Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DB-1310–Phase 1Advanced Solid TumorDec 2027
SNV1521
PARP inhibitor
–Phase 1Advanced Solid Tumor; Pancreatic CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06220864SNV1521Phase 1Advanced Solid TumorOncologyDec 2027
NCT06220864DB-1310Phase 1Advanced Solid TumorOncologyDec 2027
NCT07756281SNV1521Phase 1Pancreatic CancerOncologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.